Safety and efficacy of natalizumab in children with multiple sclerosis. by Ghezzi A et al.
DOI 10.1212/WNL.0b013e3181f11daf
 2010;75;912Neurology
A. Ghezzi, C. Pozzilli, L.M.E. Grimaldi, et al.
sclerosis
Safety and efficacy of natalizumab in children with multiple
 
May 2, 2012This information is current as of 
 
 
 http://www.neurology.org/content/75/10/912.full.html
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
 
rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
Allsince 1951, it is now a weekly with 48 issues per year. Copyright © 2010 by AAN Enterprises, Inc. 
® is the official journal of the American Academy of Neurology. Published continuouslyNeurology 
Safety and efficacy of natalizumab in
children with multiple sclerosis
A. Ghezzi, MD
C. Pozzilli, MD
L.M.E. Grimaldi, MD
V. Brescia Morra, MD
F. Bortolon, MD
R. Capra, MD
M. Filippi, MD
L. Moiola, MD
M.A. Rocca, MD
M. Rottoli, MD
P. Sarchielli, MD
M. Zaffaroni, MD
G. Comi, MD
ABSTRACT
Objective: To describe the effect of natalizumab in the treatment of subjects with active multiple
sclerosis (MS) treated before the age of 18 years.
Methods: Nineteen pediatric subjects with MS (mean age 14.6  2.2 years, mean number of
attacks 5.2  1.9 during the pretreatment phase of 27.7  19.7 months, median pretreatment
Expanded Disability Status Scale score [EDSS] 2.5, range 1.0–5.0) were treated with natali-
zumab at the dose of 300mg every 28 days. After treatment initiation, patients were reassessed
clinically every month; brain MRI was performed at baseline and every 6 months.
Results: Patients received a median number of 15 infusions (range 6–26). A transient reversible
worsening of preexisting symptoms occurred in 1 subject during and following the first infusion.
All the patients remained relapse-free during the whole follow-up. The median EDSS decreased
from 2.5 to 2.0 at the last visit (p  0.001). EDSS remained stable in 5 cases, decreased by at
least 0.5 point in 6 cases, and decreased by at least 1 point in 8 cases. At baseline, the mean
number of gadolinium-enhancing lesions was 4.1 (range 1–20). During the follow-up, no
gadolinium-enhancing lesions were detected (p  0.008); 3 patients developed new T2-visible
lesions at month 6 scan but the overall number of T2 lesions remained stable during the subse-
quent follow-up. Transient and mild side effects occurred in 8 patients.
Conclusions: Natalizumab was well-tolerated in all subjects. A strong suppression of disease ac-
tivity was observed in all subjects during the follow-up.
Classification of evidence: This study provides Class IV evidence that natalizumab, 300 mg IV
once every 28 days, decreased EDSS scores in pediatric patients withMS over amean treatment
period of 15.2 months. Neurology® 2010;75:912–917
GLOSSARY
AIFA Agenzia Italiana del Farmaco; EDSS Expanded Disability Status Scale;GA glatiramer acetate;Gd gadolinium;
IFN  interferon-; MS  multiple sclerosis; NA  natalizumab; PML  progressive multifocal leukoencephalopathy; RR 
relapsing-remitting.
Up to 10% of multiple sclerosis (MS) cases have a disease onset before the age of 18 years.1-5
The majority of these subjects have a relapsing-remitting (RR) course and experience frequent
relapses in the first phase of the disease, with a relapse rate that is nearly twice that of adult
MS.6-8 The number of relapses in the first few years is a negative prognostic factor as it corre-
lates with increased disease severity and an earlier development of the secondary progressive
phase of MS.5
Several open studies have demonstrated that drugs active in adult MS,9 such as interferon-
(IFN) and glatiramer acetate (GA), are also safe and effective in pediatric MS.5 For cases with
a poor response to IFN or GA and an aggressive MS evolution, other therapeutic options
should be considered.
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Natalizumab (NA) is emerging as one of the
most effective treatments for adult MS, with a
strong effect on clinical and MRI measures of
disease activity.10 However, the occurrence of
progressive multifocal leukoencephalopathy
(PML) in 2 patients receiving NA in combina-
tion with IFN-1a11 brought the regulatory au-
thorities to limit the use of NA to monotherapy
as a second-line treatment. Additional PML
cases have been observed during the postmarket-
ing phase with a current estimated prevalence of
1 per 1,000 treated cases.12
Information on the use of NA in pediatric
patients is scarce. The aim of this prospective
study is to evaluate the safety profile and the
effect of NA on clinical and MRI measures of
disease activity in pediatric MS.
METHODS A cooperative study group to evaluate the effects
of immunomodulatory drugs in children and adolescents with
MS was established in 2002 in Italy including all MS centers
active in the treatment of pediatric MS. In 2007, we started the
collection of all incidental cases treated in Italy with NA before
18 years of age, and included in the Agenzia Italiana del Farmaco
(AIFA) Registry: a form was created and used by all centers to
collect complete clinical and laboratory data prospectively, at
baseline and follow-up.
In line with approved guidelines for adult MS, NA was consid-
ered in 9 AIFA-approved centers in patients younger than 18 years
of age because of a severe and active evolution of the disease with
either 1) the demonstration of at least 2 relapses or the occurrence of
a severe relapse with incomplete recovery in the previous 2 years,
during treatment with IFN or GA; or 2) the demonstration of an
active MS, with at least 2 relapses in the last year and appearance of
new T2 or gadolinium (Gd)-enhancing lesions on brainMRI, with-
out any prior treatment. Fourteen patients fulfilled criterion 1, while
the remaining patients fulfilled criterion 2. All patients accepted NA
treatment after they and their parents had been carefully informed
of related risks and advantages.
The aim of the study was to evaluate the frequency of re-
lapses during the treatment with NA, to record modification of
Expanded Disability Status Scale score (EDSS), T2, and Gd-
enhancing lesions on MRI, and to collect data an adverse events.
NA was administered every 28 days according to manufac-
turer’s guidelines. Since body weight was 50 kg in all subjects,
the same dose given in adults was administered. Complete blood
cell count, hepatic and renal function, as well as clinical evalua-
tion with rating of the EDSS score13 were assessed monthly. In
each patient, conventional brain MRI (dual-echo and postcon-
trast T1-weighted scans) was performed at entry and every 6
months locally using 1.5-Tesla scanners. In each center, the same
scanner and a standardized MRI acquisition protocol were used
for the entire study duration. The MRI sequences were posi-
tioned to run parallel to a line that joins the most inferoanterior
and inferoposterior parts of the corpus callosum. On follow-up
scans, obtained with the same machine and the same technical
protocol, patients were carefully repositioned according to pub-
lished guidelines.14 The evaluation of MRI scans was centralized
at the Neuroimaging Research Unit, Hospital S. Raffaele. Gd-
enhancing lesions were identified by consensus by 2 experienced
observers, blinded to patients’ clinical status.15 The number of
total Gd-enhancing lesions at baseline and the number of total
and new Gd-enhancing lesions on follow-up scans were counted.
The number of new T2-weighted lesions on follow-up scans was
also assessed.
Standard protocol approvals and patient consents. The
study was conducted in accordance with the International Con-
ference on Harmonisation Guidelines of Good Clinical Practice
and the Declaration of Helsinki. The protocol received approval
from an ethical standards committee on human experimentation
for any experiment using human subjects (ethical committee of
the coordinating center). Written informed consent was ob-
tained from each patient participating in the study (consent for
research) and her or his parents.
RESULTS Nineteen subjects (12 girls) with a mean
age at onset of 12.4 (SD  2.6) years were included
in the study. They received NA a mean of 27.7
(SD  19.7) months after the onset of the disease
(median 19), and after 5.2 (SD  1.9) clinical epi-
sodes had occurred (median 6.0). The mean number
of attacks in the year that preceded the treatment
with NA was 3.1 (SD  1.6) (median 2.0). The
main demographic and clinical findings of each pa-
tient are reported in table 1, and the findings of the
whole cohort of patients are summarized in table 2.
Fourteen cases had been previously treated with
other agents: IFN (12 cases) and GA (4 cases) were
stopped a mean of 38 days (range 28–70) prior to
starting NA. The interval between mitoxantrone
withdrawal (2 cases) and NA initiation was 16 and
36 months. Five patients with a mean EDSS 2.2, a
mean number of 2.8 relapses during the mean pre-
treatment period of 14 months, and a mean number
of 11 Gd-enhancing lesions at baseline (median 7)
did not receive any treatment before NA initiation.
Patient 15, with only 2 relapses and an EDSS  1,
was treated with NA because of the high number of
new T2 and Gd-enhancing lesions (20) in 3 se-
quential scans, 1–2 months apart, even after a course
of high-dose methylprednisolone IV.
NA administration was scheduled every 28 days,
but in some cases the infusion was delayed by a few
days because of fever in the previous days or school/
holidays problems. A total of 15.4 (SD  5.6) infu-
sions (median 15) were performed during a mean
follow-up of 15.2 months (median 16). Thirteen pa-
tients had a follow-up longer than 12 months (mean
18.0, median 17.0, range 13–25).
No relapses occurred in the entire cohort during
the treatment with NA, and only 1 subject experi-
enced a transitory worsening of preexisting symp-
toms during and immediately after the first
administration of NA (no treatment required). NA
was stopped for family reasons in patient 10 after 12
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months of treatment, but NA restarted 9 months
later, after new Gd-enhancing lesions appeared.
The mean EDSS was 2.6 (SD  1.0) before the
treatment (median 2.5, range 1.0–5.0), and it de-
creased to 1.9 (SD  1.0) at the last visit (median
2.0, range 0–3.5) (p  0.001). EDSS remained sta-
ble in 5 cases, decreased by at least 0.5 point in 6
cases, and decreased by at least 1 point in 8 cases.
Ten adverse events (headache in 3 patients, ver-
tigo in 2, and pharyngitis, itching, nausea, diarrhea,
and fatigue each in 1 patient) were observed in 8 out
of 19 patients. All the previous adverse events re-
solved spontaneously and no medication was re-
quired. In 3 cases, leukocyte count increased slightly,
but under twice the upper normal limit, and no other
hematologic abnormality was found.
At baseline, 11 pediatric MS patients had Gd-
enhancing lesions (mean number of lesions 4.1,
range 1–20). During the follow-up, none of the pa-
tients showed any Gd-enhancing lesions (p 0.008,
paired t test); only 3 patients developed new T2-
visible lesions at month 6 scan (1 lesion in a patient
with 7 Gd-enhancing lesions on baseline scan, 4 le-
sions in a patient with 7 Gd-enhancing lesions on
baseline scan, and 3 lesions in a patient without Gd-
enhancing lesions on the baseline scan). No new T2
or Gd-enhancing lesions were detected on the 12-
month MRI scans of the 13 patients with such a
Table 1 Main clinical features of the 19 patients with pediatric MS receiving NA
Patient
no. Gender
Previous
immunomodulatory
medications
Age at
MS
onset,
y
Pre-NA
disease
duration,
mo
Total
no. of
pre-NA
attacks
No. of attacks
in the year
prior to NA
treatment
No. of NA
infusions
Pre-NA
EDSS
EDSS at
the last
observation
1 F Rebif 22 g,
Rebif 44 g
14 12 6 6 16 2.5 1.5
2 F Avonex, Rebif 22 g 12 63 8 5 17 2.5 2.0
3 F Mitoxantrone,a
Rebif 22 g, Copaxone
10 59 6 2 11 5.0 4.0
4 M Mitoxantrone,b
Copaxone
13 19 6 3 10 2.0 1.0
5 F Copaxone 14 15 6 5 15 1.0 0
6 F Betaferon 14 15 5 4 14 2.0 1.5
7 F Avonex 11 41 4 2 9 2.0 2.0
8 F Rebif 22 g,
Betaferon, Copaxone
10 77 6 1 14 4.0 3.5
9 M Avonex, Betaferon 14 29 6 2 13 1.5 1.5
10 F Avonex, Rebif 22 g 11 17 10 6 26 3.0 1.5
11 M Avonex 6 36 6 2 11 3.5 3.0
12 M Betaferon,
Rebif 22 g
16 14 6 5 26 3.5 2.0
13 M Avonex, Rebif 22 g 14 24 4 1 16 2.0 2.0
14 F Rebif 22 g 10 36 5 4 21 3.5 2.0
15 F — 12 12 2 2 6 1.0 0
16 M — 14 6 3 3 23 3.0 2.5
17 F — 16 15 3 2 16 2.0 2.0
18 M — 11 17 3 2 10 2.5 2.5
19 F — 11 20 4 2 18 2.5 2.0
Abbreviations: EDSS Expanded Disability Status Scale; MSmultiple sclerosis; NA natalizumab.
a Cumulative dose 30 mg/m2 36 months before NA, as induction therapy.
b Only 1 administration, stopped because of severe lymphopenia 16 months before NA initiation.
Table 2 Baseline demographic and clinical
features of 19 patients with
pediatric MS receiving NA
Characteristics Mean (SD)
Age at MS onset, y 12.4 (2.6)
Pre-NA disease duration, mo 27.7 (19.7)
Age at onset of NA treatment, y 14.6 (2.2)
Weight, Kg 63 (12)
Height, cm 166 (10)
No. of attacks, including the
first episode
5.2 (1.9)
No. of attacks in the year prior to
NA treatment
3.1 (1.6)
Abbreviations: MSmultiple sclerosis; NA natalizumab.
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follow-up scan, and on subsequent scans for the 4
patients with a longer follow-up.
DISCUSSION In this observational Class IV study, 19
pediatric MS patients with a mean age of 14.6 years
were treated with NA because of an active form of MS,
as suggested by the high number of relapses after the
onset of the disease and during the year that preceded
NA therapy. The whole disease duration was relatively
short; furthermore, the majority of the patients had
MRI activity, quantified as Gd-enhancing lesions at
baseline. Twelve of 14 patients experienced 2 or more
relapses in the year prior to NA initiation while they
were receiving a first-line treatment and, according to
another study in pediatric MS,16 they were considered
as nonresponders. Two patients did not fit this defini-
tion but they increased their EDSS score by 1 point
after the last relapse and developed new and active brain
MRI lesions. Five cases received NA as first-line treat-
ment because of the occurrence of 2 or more relapses
prior to NA treatment, rapid progression of EDSS
score, and demonstration of MRI activity, with a me-
dian of 7 Gd-enhancing lesions.
After a mean follow-up of 15 months, we ob-
served a dramatic decrease of disease activity: no re-
lapse occurred and only 1 patient experienced a
transitory worsening of preexisting symptoms during
and immediately after the first administration, with
spontaneous recovery. The median EDSS decreased
from 2.5 to 2.0 at the end of the follow-up: it de-
creased by at least 0.5 in 14 cases and was unchanged
in 5 patients. Brain MRI was performed every 6
months and no Gd-enhancing activity was observed.
These data suggest that disease activity was
strongly suppressed in all cases for the entire
follow-up duration. We could confirm, in a higher
number of subjects, the positive results observed in 1
patient treated for 12 months,17 in another case
treated for 15 months,18 and in 3 cases treated for 15,
16, and 24 months.19
This powerful effect of NA in reducing disease
activity in pediatric MS is likely due to the predomi-
nant inflammatory pattern of the disease in this
age.20,21 If inflammation is suppressed, the nervous
tissue can be reinforced in its capability to compen-
sate damage,22 and can be protected from irreversible
brain damage, which is less severe and less diffuse at
this age, compared to adult MS.23,24 On the other
hand, recent subgroup analysis of data from the
AFFIRM study support the use of NA in patients
with more severe relapsing disease.25 Therefore, it is
not surprising to observe a great effect of NA in pedi-
atric MS with a very high disease activity.
The favorable clinical evolution and the good tol-
erability of NA was confirmed in the 13 patients who
received more than 12 infusions: no relevant side ef-
fects were found, and all patients remained disease-
free, according to the definition of absence of relapses
and disease progression, and no new or Gd lesions.
The treatment was well-tolerated and well-accepted
in all cases. Adverse events were recorded in 8 subjects;
they were mild and transitory, and no additional medi-
cation was required. The dose of NA was the same used
in adults, and it was not necessary to reduce it during
the follow-up, but the reduction of NA from 5 mg/kg
to 3 mg/kg of body weight is suggested if adverse events
occur during the treatment.19
Cyclophosphamide has also been proposed as a
second-line treatment for active pediatric MS in a
retrospective study of 17 subjects with a mean age of
15 years and a mean disease duration of 3.1 years.16
EDSS score was reduced after 1 year in most cases.
Three children remained relapse-free, and 12 re-
duced their annualized relapse rate from 3.8 to 1.6.
Adverse events were frequent (nausea and vomiting
in 15 patients, lymphopenia in 16, anemia in 10,
alopecia in 10, menstrual disorders in 5 out of 10
girls; in rare cases, thrombocytopenia, hematuria, in-
fections, fatigue, urticaria, and myalgias); they were
severe in a few patients (amenorrhea in 3, sterility in
1, osteoporosis in 2, bladder cancer in 1). For these
reasons, the authors concluded that cyclophospha-
mide should be considered a second-line treatment
for carefully selected and monitored children with
aggressive MS refractory to first-line therapies. Our
data, observed in a cohort of patients with similar
age, disease duration, and number of relapses prior to
treatment initiation, suggest that the short-term tol-
erability and clinical efficacy of NA treatment are
more favorable in comparison to cyclophosphamide.
NA was also safe and well-tolerated in a cohort of 38
pediatric patients with Crohn disease.26
A major concern of NA treatment is the possible
occurrence of PML and other potential long-term
adverse events such as malignancies and severe infec-
tions. Their frequency, severity, and relationship
with age, disease duration, NA exposure, previous
treatments, and other possible risk factors will be
clarified by the many ongoing surveillance studies in
adult MS. The incidence of PML increases with the
duration of NA use, and it has been confirmed to be
nearly 1 case per 1,000.27The median treatment du-
ration to onset of symptoms of PML was 25 months
in the 28 cases of confirmed PML reported up to
November 2009.27 In this cohort, only 1 patient was
younger than 27 years of age. In Italy, a surveillance
program has been implemented by the Regulatory
Authority. So far, no relevant side effects have been
recorded in more than 2,000 patients with adult-
onset MS treated with NA.28 The small number of
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our pediatric patients with MS does not allow defini-
tion of the safety profile of NA in children. Further
multinational long-term studies are required to clar-
ify definitively if virus exposure during late child-
hood–early adolescence29 involves a different risk of
PML. If risks will be acceptable, NA could become
the first-choice agent for second-line treatment in se-
lected children and adolescents with active MS, due
to its overall good tolerability, easy regimen of ad-
ministration, and efficacy.
An open question in pediatric MS is how long to
continue the treatment with NA: most subjects had
been previously treated with first-line, and some-
times with other second-line agents, without suffi-
cient benefit: if safety data will be reassuring, NA
could be continued, with a careful monitoring of ad-
verse events. Our study group plans to continue
long-term follow-up of patients included in this
study, and to enroll new subjects treated with NA in
our database, in order to help clarify these issues.
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